药物警戒软件市场：现状分析与预测（2022-2028 年）

在预测期内，全球药物警戒软件市场规模预计将以 8% 左右的增长率增长。 药物警戒有助于药物不良反应的早期发现和自发报告，是监测和评估药物不良反应的过程，是有效药物监管体系、公共卫生计划和临床研究计划的重要组成部分。 为满足客户要求，药物警戒软件供应商提供了单独且完整的解决方案。 癌症患者的增加正在推动报告系统和药物警戒新技术以及研发和临床研究项目的变革，从而推动市场的增长。

本报告审视了全球药物警戒软件市场，并按功能、交付方式、最终用户、地区和进入市场的公司概况提供了市场概况以及趋势。

内容

第一章市场介绍

第2章研究方法或假设

第三章市场总结

第 4 章执行摘要

第 5 章 COVID-19 对药物警戒软件的影响

第 6 章药物警戒软件市场收入，2020-2028

第 7 章功能市场洞察

• 不良事件报告软件
• 药物安全审计软件
• 问题跟踪软件
• 完全集成的软件

第 8 章交付模式的市场洞察

• 现场交付
• 按需/基于云的 (SaaS) 交付

第 9 章最终用户的市场洞察

• 製药和生物技术公司
• 首席风险官
• 业务流程外包公司
• 其他

第 10 章按地区划分的市场洞察

• 北美
• 欧洲
• 亚太地区
• 其他地区

第 11 章药物警戒软件市场动态

• 市场驱动力
• 市场挑战
• 影响分析

第 12 章药物警戒软件的市场机会

第 13 章药物警戒软件市场趋势

第14章需求侧与供给侧分析

第 15 章价值链分析

第16章价格分析

第 17 章战略洞察

第 18 章衝突场景

第十九章公司概况

• IQVIA Inc.
• Labcorp Drug Development
• Parexel International Corporation
• Accenture
• Cognizant
• Clario
• Thermo Fisher Scientific Inc.
• ICON plc
• Quanticate
• AB Cube S.A.S.

第20章 免责事项

The global pharmacovigilance software market is expected to grow at a significant rate of around 8% during the forecast period. Pharmacovigilance is useful in the early detection and spontaneous reporting of adverse drug reactions, and it is the process of monitoring and evaluating adverse drug reactions and it is a key component of effective drug regulation systems, public health programs and clinical research programs. To meet the requirements of customers, vendors of pharmacovigilance software offer individualized and complete solutions. These vendors are additionally providing end-to-end solutions, for example, electronic information catch, artificial intelligence, and interoperability, among others to enhance their offerings. In addition, stakeholders in the industry are moving toward the use of modern technology to help them with their pharmacovigilance tasks because of the combined pressures of volume, cost, and the increased demand for analytics.

Changing reporting systems and emerging technology in pharmacovigilance and rising cancer cases boosting the R&D and clinical research programs are driving the market growth. For instance, according to the data published by the American Cancer Society (ACS), in January 2020, around 1.8 million new cancer cases were diagnosed and 606,520 cancer deaths in the United States.

IQVIA Inc., Labcorp Drug Development, Parexel International Corporation, Accenture, Cognizant, Clario, Thermo Fisher Scientific Inc., ICON plc, Quanticate, and AB Cube S.A.S. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst functionality, adverse event reporting software category to witness robust CAGR during the forecast period"

Based on functionality, the market is segmented into adverse event reporting software, drug safety audits software, issue tracking software, and fully integrated software. Amongst, the adverse event reporting software category is to witness robust CAGR during the forecast period owing to the rising demand for safe medicines and drugs around the world on account of the increasing incidences of adverse drug reactions (ADRs) is contributing to market growth. Apart from this, due to the rapid digitization of clinical trials, there's a rise in the adoption of pharmacovigilance and medicine safety software to ensure the implementation of new methods also drives the market growth during the forecast period.

"Amongst end-users, the pharmaceutical and biotechnology companies to hold a significant share in the market in 2020"

On the basis of end-users, the market is categorized into pharmaceutical and biotechnology companies, contract research organizations, business process outsourcing firms, and others. Among these, the pharmaceutical and biotechnology companies to hold a significant share of the market in 2020. This is mainly due to the extensive research and development efforts by several pharmaceutical companies and these companies are also launching new products which will also contribute to the growth of the market. For instance, Dialog Solutions launched the next generation of pharmacovigilance literature monitoring in 2021.

In addition, multiple adverse events, or adverse reactions force research organizations to turn to pharmacovigilance services for clinical trials, raising the demand for the growth of the market during the forecast period.

"North America to hold a significant share in the market"

For a better understanding of the market adoption of the pharmacovigilance software industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to increasing Initiatives undertaken by the governments, investment in the research & development process and adoption of solutions, and the availability of major key market players in the region propelling the growth rate of the market growth during the forecast period. For instance, in 2021, the Open FDA initiative undertaken by the US government provides access to its database through open search-based programs for application developers and scientists.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

The global pharmacovigilance software market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Pharmacovigilance Software Market
• 2.2. Research Methodology of the Pharmacovigilance Software Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE PHARMACOVIGILANCE SOFTWARE MARKET

6 PHARMACOVIGILANCE SOFTWARE MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY FUNCTIONALITY

• 7.1. Adverse Event Reporting Software
• 7.2. Drug Safety Audits Software
• 7.3. Issue Tracking Software
• 7.4. Fully Integrated Software

8 MARKET INSIGHTS BY MODE OF DELIVERY

• 8.1. On-Premises Delivery
• 8.2. On-Demand/ Cloud-Based (SaaS) Delivery

9 MARKET INSIGHTS BY END-USERS

• 9.1. Pharmaceutical and Biotechnology Companies
• 9.2. Contract Research Organizations
• 9.3. Business Process Outsourcing Firms
• 9.4. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 PHARMACOVIGILANCE SOFTWARE MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 PHARMACOVIGILANCE SOFTWARE MARKET OPPORTUNITIES

13 PHARMACOVIGILANCE SOFTWARE MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICING ANALYSIS

17 STRATEGIC INSIGHTS

18 COMPETITIVE SCENARIO

• 18.1. Competitive Landscape
  • 18.1.1. Porters Fiver Forces Analysis

19 COMPANY PROFILED

• 19.1. IQVIA Inc.
• 19.2. Labcorp Drug Development
• 19.3. Parexel International Corporation
• 19.4. Accenture
• 19.5. Cognizant
• 19.6. Clario
• 19.7. Thermo Fisher Scientific Inc.
• 19.8. ICON plc
• 19.9. Quanticate
• 19.10. AB Cube S.A.S.

20 DISCLAIMER